LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex

Frontiers in Molecular Neuroscience

Volumn 7, Issue MAY, 2014, Pages

  Cirnaru, Maria D ^a,b   Marte, Antonella ^c   Belluzzi, Elisa ^d   Russo, Isabella ^d   Gabrielli, Martina ^b,e   Longo, Francesco ^f   Arcuri, Ludovico ^f   Murru, Luca ^b   Bubacco, Luigi ^d   Matteoli, Michela ^e,g   Fedele, Ernesto ^c   Sala, Carlo ^b,e   Passafaro, Maria ^b   Morari, Michele ^f   Greggio, Elisa ^d   Onofri, Franco ^c   Piccoli, Giovanni ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Kinase; LRRK2; Presynaptic vesicle; Protein interaction; Synaptic activity

Indexed keywords

EID: 84901669528     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2014.00049     Document Type: Article

References (52)

1. Aasly, J. O., Toft, M., Fernandez-Mata, I., Kachergus, J., Hulihan, M., White, L. R., et al. (2005). Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann. Neurol. 57, 762-765. doi: 10.1002/ana.20456
2. Bauer, M., Kinkl, N., Meixner, A., Kremmer, E., Riemenschneider, M., Förstl, H., et al. (2009). Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther. 16, 142-147. doi: 10.1038/gt.2008.123
3. Belluzzi, E., Greggio, E., and Piccoli, G. (2012). Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2. Biochem. Soc. Trans. 40, 1111-1116. doi: 10.1042/BST20120124
4. Berg, D., Schweitzer, K. J., Leitner, P., Zimprich, A., Lichtner, P., Belcredi, P., et al. (2005). Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 128, 3000-3011. doi: 10.1093/brain/awh666
5. Berger, Z., Smith, K. A., and Lavoie, M. J. (2010). Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49, 5511-5523. doi: 10.1021/bi100157u
6. Bosgraaf, L., and Van Haastert, P. J. (2003). Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta. 1643, 5-10. doi: 10.1016/j.bbamcr.2003.08.008
7. Brice, A. (2005). Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128, 8475-8485. doi: 10.1093/brain/awh676
8. Civiero, L., Vancraenenbroeck, R., Belluzzi, E., Beilina, A., Lobbestael, E., Reyniers, L., et al. (2012). Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS ONE 7:e43472. doi: 10.1371/journal.pone.0043472
9. Deng, J., Lewis, P. A., Greggio, E., Sluch, E., Beilina, A., and Cookson, M. R. (2008). Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U.S.A. 105, 1499-1504. doi: 10.1073/pnas.0709098105
10. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., et al. (2011). Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 7, 203-205. doi: 10.1038/nchembio.538
11. Gillardon, F., Kremmer, E., Froehlich, T., Ueffing, M., Hengerer, B., and Gloeckner, C. J. (2013). ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2? J. Neurosci. Methods 214, 62-68. doi: 10.1016/j.jneumeth.2012.12.015
12. Gloeckner, C. J., Kinkl, N., Schumacher, A., Braun, R. J., O'Neill, E., Meitinger, T., et al. (2006). The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232. doi: 10.1093/hmg/ddi439
13. Greengard, P., Valtorta, F., Czernik, A. J., and Benfenati, F. (1993). Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 259, 780-785. doi: 10.1126/science.8430330
14. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., et al. (2006). Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341. doi: 10.1016/j.nbd.2006.04.001
15. Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J.-M., Daniels, V., et al. (2008). The Parkinson disease-associated leucine-rich repeat Kinase 2 (LRRK2) Is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283, 16906-16914. doi: 10.1074/jbc.M708718200
16. Guo, L., Wang, W., and Chen, S. G. (2006). Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Int. J. Biochem. Cell Biol. 38, 1469-1475. doi: 10.1016/j.biocel.2006.02.009
17. Hardy, J., Cai, H., Cookson, M. R., Gwinn-Hardy, K., and Singleton, A. (2006). Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60, 389-398. doi: 10.1002/ana.21022
18. Herzig, M. C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., et al. (2011). LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20, 4209-4223. doi: 10.1093/hmg/ddr348
19. Hinkle, K. M., Yue, M., Behrouz, B., Dächsel, J. C., Lincoln, S. J., Bowles, E. E., et al. (2012). LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener. 7:25. doi: 10.1186/1750-1326-7-25
20. Huttner, W. B., Schiebler, W., Greengard, P., and De Camilli, P. (1983). Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J. Cell Biol. 96, 1374-1388. doi: 10.1083/jcb.96.5.1374
21. Ito, G., and Iwatsubo, T. (2012). Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem. J. 441, 987-994. doi: 10.1042/BJ20111215
22. Klein, C. L., Rovelli, G., Springer, W., Schall, C., Gasser, T., and Kahle, P. J. (2009). Homo-and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J. Neurochem. 111, 703-715. doi: 10.1111/j.1471-4159.2009.06358.x
23. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature227, 680-685. doi: 10.1038/227680a0
24. Li, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., et al. (2010). Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 30, 1788-1797. doi: 10.1523/JNEUROSCI.5604-09.2010
25. Luerman, G. C., Nguyen, C., Samaroo, H., Loos, P., Xi, H., Hurtado-Lorenzo, A., et al. (2014). Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J. Neurochem. 128, 561-576. doi: 10.1111/jnc.12483
26. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., and Abeliovich, A. (2006). The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593. doi: 10.1016/j.neuron.2006.10.008
27. Marte, A., Cavallero, A., Morando, S., Uccelli, A., Raiteri, M., and Fedele, E. (2010). Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis. J. Neurochem. 115, 343-352. doi: 10.1111/j.1471-4159.2010.06923.x
28. Marti, M., Paganini, F., Stocchi, S., Mela, F., Beani, L., Bianchi, C., et al. (2003). Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. J. Neurochem. 84, 792-802. doi: 10.1046/j.1471-4159.2003.01569.x
29. Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., et al. (2012). LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75, 1008-1021. doi: 10.1016/j.neuron.2012.08.022
30. Matteoli, M., Takei, K., Perin, M. S., Sudhof, T. C., and De Camilli, P. (1992). Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons. J. Cell Biol. 117, 849-861. doi: 10.1083/jcb.117.4.849
31. Mela, F., Marti, M., Ulazzi, L., Vaccari, E., Zucchini, S., Trapella, C., et al. (2004). Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. Eur. J. Neurosci. 19, 1317-1324. doi: 10.1111/j.1460-9568.2004.03220.x
32. Melrose, H. L., Dächsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., et al. (2010). Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 40, 503-517. doi: 10.1016/j.nbd.2010.07.010
33. Messa, M., Congia, S., Defranchi, E., Valtorta, F., Fassio, A., Onofri, F., et al. (2010). Tyrosine phosphorylation of synapsin I by Src regulates synaptic-vesicle trafficking. J. Cell Sci. 123, 2256-2265. doi: 10.1242/jcs.068445
34. Migheli, R., Del Giudice, M. G., Spissu, Y., Sanna, G., Xiong, Y., Dawson, T. M., et al. (2013). LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS ONE 8:e77198. doi: 10.1371/journal.pone.0077198
35. Moore, D. J., West, A. B., Dawson, V. L., and Dawson, T. M. (2005). Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87. doi: 10.1146/annurev.neuro.28.061604.135718
36. Nichols, R. J., Dzamko, N., Hutti, J. E., Cantley, L. C., Deak, M., Moran, J., et al. (2009). Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 424, 47-60. doi: 10.1042/BJ20091035
37. Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., et al. (2010). 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393-404. doi: 10.1042/BJ20100483
38. Onofri, F., Messa, M., Matafora, V., Bonanno, G., Corradi, A., Bachi, A., et al. (2007). Synapsin phosphorylation by SRC tyrosine kinase enhances SRC activity in synaptic vesicles. J. Biol. Chem. 282, 15754-15767. doi: 10.1074/jbc.M701051200
39. Orenbuch, A., Shalev, L., Marra, V., Sinai, I., Lavy, Y., Kahn, J., et al. (2012). Synapsin selectively controls the mobility of resting pool vesicles at hippocampal terminals. J. Neurosci. 32, 3969-3980. doi: 10.1523/JNEUROSCI.5058-11.2012
40. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600. doi: 10.1016/j.neuron.2004.10.023
41. Piccoli, G., Condliffe, S. B., Bauer, M., Giesert, F., Boldt, K., De Astis, S., et al. (2011). LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 31, 2225-2237. doi: 10.1523/JNEUROSCI.3730-10.2011
42. Piccoli, G., Onofri, F., Cirnaru, M. D., Kaiser, C. J. O., Jagtap, P., Kastenmüller, A., et al. (2014). LRRK2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol. Cell. Biol. doi: 10.1128/MCB.00914-13. [Epub ahead of print].
43. Piccoli, G., Verpelli, C., Tonna, N., Romorini, S., Alessio, M., Nairn, A. C., et al. (2007). Proteomic analysis of activity-dependent synaptic plasticity in hippocampal neurons. J. Proteome Res. 6, 3203-3215. doi: 10.1021/pr0701308
44. Reith, A. D., Bamborough, P., Jandu, K., Andreotti, D., Mensah, L., Dossang, P., et al. (2012). GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg. Med. Chem. Lett. 22, 5625-5629. doi: 10.1016/j.bmcl.2012.06.104
45. Sen, S., Webber, P. J., and West, A. B. (2009). Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. 284, 36346-36356. doi: 10.1074/jbc.M109.025437
46. Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., et al. (2012). Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4:164ra161. doi: 10.1126/scitranslmed.3004485
47. Shin, N., Jeong, H., Kwon, J., Heo, H. Y., Kwon, J. J., Yun, H. J., et al. (2008). LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 314, 2055-2065. doi: 10.1016/j.yexcr.2008.02.015
48. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., et al. (2009). R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U.S.A. 106, 14622-14627. doi: 10.1073/pnas.0906334106
49. Verderio, C., Coco, S., Rossetto, O., Montecucco, C., and Matteoli, M. (1999). Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes. J. Neurochem. 73, 372-379. doi: 10.1046/j.1471-4159.1999.0730372.x
50. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., et al. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842-16847. doi: 10.1073/pnas.0507360102
51. Yun, H. J., Park, J., Ho, D. H., Kim, H., Kim, C.-H., Oh, H., et al. (2013). LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp. Mol. Med. 45, e36. doi: 10.1038/emm.2013.68
52. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607. doi: 10.1016/j.neuron.2004.11.005